EMEA-000694-PIP05-20

Key facts

Invented name
Forxiga
Active substance
dapagliflozin
Therapeutic area
Infectious diseases
Decision number
P/0444/2020
PIP number
EMEA-000694-PIP05-20
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

Tel. +46 8553 27591
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating